These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 27092564)
1. Care of Patients With HIV Infection: Antiretroviral Drug Regimens. Bolduc P; Roder N; Colgate E; Cheeseman SH FP Essent; 2016 Apr; 443():23-30. PubMed ID: 27092564 [TBL] [Abstract][Full Text] [Related]
2. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients. Manfredi R; Calza L AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748 [TBL] [Abstract][Full Text] [Related]
3. An update and review of antiretroviral therapy. Piacenti FJ Pharmacotherapy; 2006 Aug; 26(8):1111-33. PubMed ID: 16863488 [TBL] [Abstract][Full Text] [Related]
5. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. Patel N; Abdelsayed S; Veve M; Miller CD Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025 [TBL] [Abstract][Full Text] [Related]
6. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients. Hill A; Sawyer W HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663 [TBL] [Abstract][Full Text] [Related]
7. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results. Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States. Brogan AJ; Talbird SE; Cohen C Value Health; 2011; 14(5):657-64. PubMed ID: 21839403 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM; J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627 [TBL] [Abstract][Full Text] [Related]
11. Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study. Masiá M; Padilla S; Barber X; Sanchis M; Terol G; Lidón F; Gutiérrez F Medicine (Baltimore); 2016 Mar; 95(11):e3108. PubMed ID: 26986155 [TBL] [Abstract][Full Text] [Related]
12. Simplification of combination antiretroviral therapy (cART) and the brain-a real-life experience. Arendt G; Schlonies S; Orhan E; Stüve O J Neurovirol; 2019 Apr; 25(2):174-182. PubMed ID: 30628025 [TBL] [Abstract][Full Text] [Related]
13. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC; AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047 [TBL] [Abstract][Full Text] [Related]
14. Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy. Miller CD; El-Kholi R; Faragon JJ; Lodise TP Pharmacotherapy; 2007 Oct; 27(10):1379-86. PubMed ID: 17896893 [TBL] [Abstract][Full Text] [Related]
15. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Else LJ; Taylor S; Back DJ; Khoo SH Antivir Ther; 2011; 16(8):1149-67. PubMed ID: 22155899 [TBL] [Abstract][Full Text] [Related]
17. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ; Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988 [TBL] [Abstract][Full Text] [Related]
18. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine. Cahn P; Vibhagool A; Schechter M; Soto-Ramirez L; Carosi G; Smaill F; Jordan JC; Pharo CE; Thomas NE; Steel HM Curr Med Res Opin; 2004 Jul; 20(7):1115-23. PubMed ID: 15265256 [TBL] [Abstract][Full Text] [Related]
19. The development of anti-HIV-1 drugs. Lu XF; Chen ZW Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415 [TBL] [Abstract][Full Text] [Related]
20. Recent advances in antiretroviral therapy and HIV infection monitoring. Schmit JC; Weber B Intervirology; 1997; 40(5-6):304-21. PubMed ID: 9675636 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]